Modus Therapeutics AB, a Karolinska Development portfolio company developing treatments for sickle cell disease, has appointed Ellen K. Donnelly as CEO. Donnelly joins from Pfizer, Inc, where she most recently was responsible for Clinical Operations for the Neuroscience and Pain therapeutic area.
Abivax shares jump on new Phase IIa HIV data
Latest NewsThe French biotech said that its lead therapeutic candidate demonstrated the first reduction in HIV reservoirs ever observed in chronically infected HIV patients. Following the news, the companys share price more than doubled.
Verona Pharma raised US-$77.8m at NASDAQ
Latest NewsBritish respiratory disease specialist Verona Pharma plc (VRNA) has raised US-$77.8m (€73,96m) at NASDAQ through the issuance of 5,768,000 American Depositary Shares (ADS) – each ADS representing eight ordinary shares – at a price of US-$13.50 per ADS.
Modus Therapeutics: Clinical development pro
AppointmentsModus Therapeutics AB, a Karolinska Development portfolio company developing treatments for sickle cell disease, has appointed Ellen K. Donnelly as CEO. Donnelly joins from Pfizer, Inc, where she most recently was responsible for Clinical Operations for the Neuroscience and Pain therapeutic area.
EuropaBio: Regulatory experience
AppointmentsEpigenomics in €171m take-over
Latest NewsBioiberica: A boost to the company
AppointmentsIn April, Luis Solera assumes the position of CEO at Barcelona-based biotech Bioiberica. He joins from LIPSA, a leading family business in the oils and fats sector.
Euronext-listed Argenx plans €68.6m IPO in the US
Latest NewsBelgian-Dutch antibody developer Argenx N.V. seeks to raise US$74.7m in a US IPO. The company, which is already listed on Euronext wants to use the proceeds to push development of its autoimmune and cancer drugs.
Longevity: Healthy ageing
BackgroundThe SIDUS® technology platform
ProductsOriginates from the in-depth experience and complete protocol system concerning the manufacture of viral vectors for vaccines or gene therapy.
EMA backs authorisation of biologics
Latest NewsFour orphan drugs, three biosimilars, and one monoclonal antibody therapy have been recommended for EU market approval by the European Medicines Agencys CHMP this month.